Previous 10 | Next 10 |
Updated imetelstat data from IMerge Phase 2 describe significant continuous durable transfusion independence, meaningful reduction in mutational burden and progression-free survival, which indicate disease-modifying activity Ongoing Phase 3 IMerge clinical trial of imetelstat desi...
Geron press release ( NASDAQ: GERN ): Q3 GAAP EPS of -$0.10 misses by $0.01 . Revenue of $0.3M (+172.7% Y/Y) beats by $0.21M . Company had approximately $195 million in cash and marketable securities. Company continues to expect total operating expenses in ...
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024 Conference Call Scheduled for 9:00 a.m....
Penny Stocks With News Today Penny stocks are some of the most exciting assets to trade if you know what you’re doing. There’s no secret that they’ve got a higher risk profile than your average stocks. But you can’t argue with the fact that on any given day, ...
Clinical-stage biotech Geron Corporation ( NASDAQ: GERN ) traded higher Friday morning after Wedbush Securities launched its coverage with an Outperform recommendation citing the company’s only product candidate, imetelstat. Geron ( GERN ) is advancing the telom...
Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will hos...
Summary Geron has been developing its lead (and only) candidate Imetelstat for some time. A partnership with Johnson & Johnson subsidiary Janssen was terminated in 2018, despite some promising data in low-risk Myelodysplastic Syndrome. Imetelstat will now read out Phase 3 ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology and Biomanufacturing I...
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present...
A Penny Stocks Watch List To Kick-Start September Are you putting together a list of penny stocks to watch for September? If you are, then you’re not alone, and this article will break down a few stocks under $5 that traders are watching at the start of September. Indeed, all...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...